Search Results
BEACON CRC: first-line bevacizumab in colorectal cancer treatment
DKN-01 with bevacizumab and chemotherapy in advanced CRC
FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRC
Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Bevacizumab or EGFR antibodies
Upfront Bevacizumab and Cetuximab Compared in Metastatic Colorectal Cancer
Dr. Bekaii-Saab Discusses an Analysis of Bevacizumab or Cetuximab for CRC
Dr. Eng Discusses the BEACON CRC Study in BRAF-Mutated CRC
BREAKWATER: encorafenib plus cetuximab in patients with BRAF V600E-mutant mCRC
First-line durvalumab + monalizumab in microsatellite-stable CRC
Colorectal Cancer Debate: First Line BRAF V600E - FOLFOXIRI/Bev
Case 1: BRAF-Mutated Metastatic Colorectal Cancer
Initial Management of Metastatic CRC in 2019
